Kawasaki disease
Article Sidebar
Main Article Content
Abstract
Background
Kawasaki disease is a vasculitis of unknown etiology, first described by Tomisaku Kawasaki in January 1961. During the decade of the 1960s it was called "ocular mucocutane-ous syndrome" or "mucocutaneous lymph-node syndrome". In 1974 Kawasaki published the first report of 50 patients, from which the disease was renamed with the eponymous currently in use. Kawasaki's disease had an initial presentation as a national epidemic, but currently occurs as regional outbreaks. It is a clinical entity poorly diagnosed in our setting, which can be attributed in part to limited knowledge about the diagnostic criteria by health professionals.
Summary of cases
We conducted a review of clinical records for the years 2007 to 2009 of children less than five years of age who had a feverish syndrome or exanthemáta's viral features, identifying four who were diagnosed as Kawasaki disease. The most common clinical manifestations were fever and changes in the oropharynx (100% of the cases), alterations in palms and soles polymorphic erythema (75%), and conjunctival injection and cervical adenop-athy (50%). Two of the patients presented echo-cardiograms coronary alterations.
Conclusions
The appropriate use of clinical criteria is the most important tool for the health professional to diagnose of Kawasaki disease and prevent associated complications.
Downloads
Article Details
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
2. Castro de Aparecida P, Carvalho I, Ferreira L. Kawasaki disease. An Bras Dermatol. 2009;84:317-31.
3. Parrillo JS. Emedicine. Pediatrics, Kawasaki disease. Emedicine 2010. Fecha de consulta: 15 de septiembre de 2010. Disponible en: http://emedicine.medscape.com/article/804960-overview.
4. Dong SK. Kawasaki disease. Yonsei Med J 2006;47:759-72.
5. Scheinfeld SN, Jones EL. Kawasaki disease. Emedicine. 2011. Fecha de consulta: 15 de septiembre de 2010. Disponible en: http://emedicine.medscape.com/article/965367-overview.
6. Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: Role of matrix metalloproteinases. Arch Dis Child. 2006;91:847-85.
7. Burns CJ. The riddle of Kawasaki disease. N Engl J Med. 2007; 356:659-61.
8. Freeman A, Stanford S. Kawasaki disease: Summary of the American Heart Association Guidelines. Am Fam Physician. 2006;74:1141-8.
9. Ocampo DP, Santacoloma G, Jaramillo F. Enfermedad de Kawasaki. Rev Asoc Colomb Dermatol. 2010;18:48-50.
10. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LL, Burn JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-71.
11. Hollman RC, Belay E, Christensen KY, Folkema AM, Steiner C, Schongberger L. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J.2010;29:483-8.